MRZM (Marizyme) FCF Margin %: 0.00% (As of Sep. 2024)


MRZM Marizyme Inc MRZM
12 GF Score
Price $0.00
View Full Analysis

What is Marizyme FCF Margin %?

Marizyme MRZM -99.67% 12 FCF Margin % is 0.00% as of Sep. 2024. GuruFocus rates MRZM with a GF Score™ of 12/100.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Marizyme's Free Cash Flow for the three months ended in Sep. 2024 was $-0.98 Mil. Marizyme's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Marizyme's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Marizyme's current FCF Yield % is 0.00%.

The historical rank and industry rank for Marizyme's FCF Margin % or its related term are showing as below:

MRZM' s FCF Margin % Range Over the Past 10 Years
Min: -2032.07   Med: 0   Max: 0
Current: -2032.07

MRZM's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -84.65 vs MRZM: -2032.07

Marizyme FCF Margin % Related Terms

Marizyme FCF Margin % Historical Data

* Premium members only.

The historical data trend for Marizyme's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme FCF Margin % Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1,712.18 -2,755.71 -4,657.51 -725.23

Marizyme Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -633.52 -803.97 -2,451.52 0.00 0.00

MRZM vs CNBX, XSNX, NBIO: FCF Margin % Comparison

For the Biotechnology subindustry, Marizyme's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marizyme FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Marizyme's FCF Margin % falls into.


MRZM
12GF Score
Marizyme Inc MRZM
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marizyme FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Marizyme's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-4.685/0.646
=-725.23 %

Marizyme's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.983/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Marizyme (MRZM) has a FCF Margin % of 0.00% as of Sep. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Marizyme and its competitors.
Is Marizyme's FCF Margin % too high?
Marizyme's current FCF Margin % is 0.00%. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Marizyme's FCF Margin % compare to CNBX and XSNX?
Marizyme's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Marizyme and its competitors. Marizyme's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marizyme stock overvalued right now?
Marizyme (MRZM) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Marizyme (MRZM), the current FCF Margin % is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marizyme Business Description

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score

Get the complete analysis for MRZM

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price